Catalogo dei prodotti della ricerca

RIGGIO, Oliviero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.576
EU - Europa 4.236
AS - Asia 2.656
AF - Africa 317
SA - Sud America 267
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 21.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.315
IT - Italia 1.730
SG - Singapore 1.369
IN - India 628
CN - Cina 509
DE - Germania 478
UA - Ucraina 404
SE - Svezia 355
FI - Finlandia 349
RU - Federazione Russa 302
BJ - Benin 204
BR - Brasile 181
GB - Regno Unito 141
CA - Canada 136
BG - Bulgaria 123
FR - Francia 94
BZ - Belize 93
TG - Togo 73
IE - Irlanda 72
AR - Argentina 59
ID - Indonesia 50
NL - Olanda 43
BE - Belgio 29
MX - Messico 28
AT - Austria 23
ZA - Sudafrica 21
RO - Romania 17
CH - Svizzera 15
TR - Turchia 15
ES - Italia 11
PK - Pakistan 10
UZ - Uzbekistan 8
AL - Albania 7
HK - Hong Kong 7
BD - Bangladesh 6
CZ - Repubblica Ceca 6
HR - Croazia 6
CL - Cile 5
EC - Ecuador 5
IQ - Iraq 5
LT - Lituania 5
MA - Marocco 5
PL - Polonia 5
TW - Taiwan 5
EU - Europa 4
KG - Kirghizistan 4
KR - Corea 4
PH - Filippine 4
PT - Portogallo 4
PY - Paraguay 4
SC - Seychelles 4
VE - Venezuela 4
CO - Colombia 3
IL - Israele 3
KZ - Kazakistan 3
OM - Oman 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
VN - Vietnam 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
DK - Danimarca 2
EG - Egitto 2
GR - Grecia 2
HU - Ungheria 2
JO - Giordania 2
JP - Giappone 2
KE - Kenya 2
LV - Lettonia 2
NO - Norvegia 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
DZ - Algeria 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
Totale 21.059
Salva come PNG Salva come JPEG
Città #
Fairfield 2.083
Woodbridge 951
Ashburn 933
Chandler 796
Houston 716
Seattle 704
Singapore 687
Cambridge 673
Wilmington 657
Ann Arbor 488
Dearborn 434
Princeton 430
Fremont 392
San Paolo di Civitate 364
Rome 363
Plano 293
San Jose 231
Lawrence 218
Frankfurt am Main 212
Beijing 210
Fasano 201
Millbury 192
Santa Clara 191
Jacksonville 161
San Diego 153
Boston 150
Sofia 121
Dallas 101
Moscow 96
Belize City 93
New York 93
Andover 87
Milan 81
Bremen 80
Ottawa 77
Lomé 73
Helsinki 68
Cosenza 66
Dublin 65
Federal 52
Saint Louis 52
Toronto 52
Des Moines 49
Norwalk 48
Jakarta 47
San Mateo 46
Boardman 45
Falls Church 42
Atlanta 40
Los Angeles 38
Southend 36
Falkenstein 35
Hefei 34
Nanjing 33
Chicago 29
Columbus 27
Brussels 26
Bühl 26
Yubileyny 26
Jinan 25
Naples 25
Council Bluffs 24
Kunming 23
Washington 22
Guangzhou 21
London 21
Nuremberg 19
Mannheim 18
Nanchang 18
Vienna 16
Mexico City 15
Auburn Hills 14
Bologna 14
Florence 13
Johannesburg 13
Phoenix 12
São Paulo 11
Indiana 10
Padova 10
Shanghai 10
Fuzhou 9
Istanbul 9
Amsterdam 8
Baotou 8
Concorezzo 8
San Nicola la Strada 8
Shenyang 8
Buffalo 7
Hong Kong 7
Pomezia 7
Tashkent 7
Turin 7
Bern 6
Cesena 6
Genzano Di Roma 6
Hebei 6
Islamabad 6
Lappeenranta 6
Orem 6
Redwood City 6
Totale 15.262
Salva come PNG Salva come JPEG
Nome #
Poliprotect vs omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions. A randomized, controlled trial 229
Semeiotica Medica e Metodologia Clinica, 3ª ed 212
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 154
Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis 145
Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension 133
Low-grade endotoxemia and platelet activation in cirrhosis 128
Management of Hepatic Encephalopathy as an Inpatient 124
Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: Time to update the guidelines? 121
Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial 121
A low muscle mass increases mortality in compensated cirrhotic patients with sepsis 117
Evidence of Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy 115
Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis 113
High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: A case-control study 110
Cirrhotic patients are at risk for health care-associated bacterial infections. 109
No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt 107
Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? 106
The animal naming test: an easy tool for the assessment of hepatic encephalopathy 106
Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors 105
Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients 105
Beta-blokers in patients with cirrhosis and infection: don't blame too soon. 104
BACTERIAL INFECTIONS AND SEPSIS ACUTELY DETERIORATE LIVER FUNCTION IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY 104
A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy 103
Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt 103
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 103
Can an incomplete stent expansion modulate the effects of TIPS? 102
Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice 102
Hemostatic balance in patients with liver cirrhosis. report of a consensus conference 101
May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease? 100
The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease 100
Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt 99
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis 98
Does nutritional status influence the outcome in patients undergoing liver transplantation in the “MELD” era? 98
Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis 98
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 97
Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis 95
CARBON TETRACHLORIDE-INDUCED EXPERIMENTAL CIRRHOSIS IN THE RAT - A REAPPRAISAL OF THE MODEL 94
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. 94
Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients 93
Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease 92
Ongoing prothrombotic state in the portal circulation of cirrhotic patients 91
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey 91
Portal Hypertension Related to Schistosomiasis Treated with a Transjugular Intrahepatic Portosystemic Shunt 91
A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients 90
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. 90
Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis 90
Clotting activation after transjugular intrahepatic portosystemic stent shunt 88
OXIDATIVE STRESS AND INFLAMMATION IN LIVER CIRRHOSIS: ROLE OF N-6/N-3 POLYUNSATURATED FATTY ACIDS BALANCE 88
Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story? 88
Nutritional status: its influence on the outcome of patients undergoing liver transplantation 88
The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt 88
Progression of low risk esophageal varices in cirrhotic patients 87
VIDEOCAPSULE ENDOSCOPY IN PATIENTS WITH PORTAL HYPERTENSION: SMALL BOWEL FINDINGS BEFORE AND FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT 87
A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis 87
A comparison of cell blood analyzer and manual hemacytometer for polymorphonuclear cell count in the ascttic fluid in cirrhotic patients with and without spontaneous bacterial peritonitis 86
Dietary and nutritional indications in hepatic encephalopathy 86
Zinc, ammonia, and Helicobacter pylori infection in liver cirrhosis. 86
IN VITRO EFFECT OF n-6/n-3 POLYUNSATURATED FATTY ACIDS ON PLATELET NOX2-MEDIATED OXIDATIVE STRESS IN LIVER CIRRHOSIS 85
An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics. A randomized trial 85
Hepatic Encephalopathy Expands the Predictivity of Meld in Liver Transplant Setting: Evidence by Means of two Independent Cohorts 85
Modification of cardiac function in cirrhotic patients with and without ascites 84
Natural history of low risk esophageal varices in cirrhotic patients 84
Idiopathic noncirrhotic portal hypertension: current perspectives 84
MELD, PROTEIN MALNUTRITION AND PREVIOUS INFECTIONS ARE PREDICTORS OF BACTERIAL INFECTIONS AND SEPSIS IN CIRRHOTIC PATIENTS 84
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (tips): PTFE-covered stent grafts versus bare stents 84
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt 83
Endoscopic screening for esophageal varices in cirrhotic patients 83
Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation 83
Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: Results of a prospective study 83
Small hepatic veins Budd-Chiari syndrome 83
Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? 83
Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis 82
PERSISTENCE OF COGNITIVE IMPAIRMENT AFTER OVERT HEPATIC ENCEPHALOPATHY: AN INTERNATIONAL, MULTI-CENTER PROSPECTIVE STUDY 82
Do We Really Need Alternatives to Polymorphonuclear Cells Counting in Ascitic Fluid? 82
Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice 82
A comparison of skinfold anthropometry and dual-energy X ray absorptiometry for the evaluation of body fat in cirrhotic patients. 82
Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass 82
Is hyperammonemia really the true cause of altered neuropsychology, brain MR spectroscopy and magnetization transfer after an oral amino acid load in cirrhosis? 82
Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis 81
Prediction of hepatic encephalopathy: Why disregard well-known risk factors? 81
Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt 81
Role of the determination of partial pressure of ammonia in cirrhotic patients with hepatic encephalopathy 80
Increased risk of cognitive impairment in cirrhotic patients with bacterial infections 80
PTFE-covered stent-grafts for tips procedure: One-year patency and clinical results 80
Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS 80
Ticlopidine-induced cholestasis 80
Hepatic encephalopathy therapy: An overview. 79
Malnutrition is a risk factor in cirrhotic patients undergoing surgery 79
Early postprandial energy expenditure and macronutrient use after a mixed meal in cirrhotic patients. 79
Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation 79
Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results 79
Accurate assessment of cardiac function and myocardial fibrosis in liver cirrhosis by contrast-enhanced cardiac magnetic resonance 79
Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. 79
Aminoacid imbalance and malnutrition in liver cirrhosis. 78
Factors predicting the presence of esophageal varices in compensated cirrhotic patients 78
PPIs in cirrhosis: more evidences for a careful prescription! 78
Quality of life in patients with minimal hepatic encephalopathy 78
Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. 78
Total and individual free fatty acid concentrations in liver cirrhosis 77
Hepatic steatosis after liver transplantation: Prevalence and associated factors 77
Erectile dysfunction in patients with liver cirrhosis 77
Totale 9.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.029 0 0 0 0 0 0 0 0 499 267 157 106
2020/20211.788 160 187 141 174 29 79 56 165 152 309 105 231
2021/20223.432 28 197 314 73 461 83 92 353 434 248 451 698
2022/20233.694 716 794 423 561 282 283 35 143 274 41 83 59
2023/20241.773 99 213 101 106 193 319 80 97 11 227 161 166
2024/20252.710 129 239 276 146 284 243 406 213 774 0 0 0
Totale 21.838